Preclinical Studies on Convalescent Human Immune Plasma-Derived Exosome: Omics and Antiviral Properties to SARS-CoV-2

Authors

Document Type

Journal Article

Publication Date

1-1-2022

Journal

Frontiers in immunology

Volume

13

DOI

10.3389/fimmu.2022.824378

Keywords

COVID-19; SARS-CoV-2; convalescence plasma; exosome; extracellular vehicles (EVs); viral treatment

Abstract

The scale of the COVID-19 pandemic forced urgent measures for the development of new therapeutics. One of these strategies is the use of convalescent plasma (CP) as a conventional source for passive immunity. Recently, there has been interest in CP-derived exosomes. In this report, we present a structural, biochemical, and biological characterization of our proprietary product, convalescent human immune plasma-derived exosome (ChipEXO), following the guidelines set forth by the Turkish Ministry of Health and the Turkish Red Crescent, the Good Manufacturing Practice, the International Society for Extracellular Vesicles, and the Gene Ontology Consortium. The data support the safety and efficacy of this product against SARS-CoV-2 infections in preclinical models.

Department

Medicine

Share

COinS